Inhaled Nitric Oxide Companies

Q: What is the global market size of Inhaled Nitric Oxide Market?

Global Inhaled Nitric Oxide market size was valued at USD 951.72 million in 2022 and is poised to grow from USD 1027 million in 2023 to USD 1755 million by 2031, at a CAGR of 7.95% in the forecast period (2024-2031).

Inhaled Nitric Oxide Market Competitive Landscape

Several significant worldwide firms vying for market supremacy define the competitive landscape of the global inhaled nitric oxide market. To improve their position in the industry, major firms like Novoteris, Linde plc, Praxair Inc., Mallinckrodt Pharmaceuticals, and Air Liquide are actively working on new products, forming strategic alliances, and merging. To take advantage of the rising demand for inhaled nitric oxide therapy globally, these companies are concentrating on broadening their product offerings and geographic reach.

Inhaled Nitric Oxide Market Top Player’s Company Profiles

Perma Pure LLC (US)

Merck KGaA (Germany)

Zylo Therapeutics Inc. (US)

HALMA PLC (UK)

Pieris Pharmaceuticals (US)

Air Liquide Healthcare (France)

Bellerophan Therapeutics Inc. (US)

Mallinckrodt Pharmaceuticals (Novoteris) (US)

Matheson Tri-Gas Inc. (US)

BOC Healthcare (UK)

Vero Biotech (US)

Nu-Med Plus Inc. (US)

Praxair Distribution Inc. (US)

LINDE PLC (UK)

Beyond Air

Taiyo Nippon Sanso Corporation

Praxair, Inc. (now part of Linde plc)

Novoteris, LLC

Nu-Med Plus, Inc.

Inhaled Nitric Oxide Market

FAQs

Inhaled Nitric Oxide market size was valued at USD 951.72 million in 2022 and is poised to grow from USD 1027 million in 2023 to USD 1755 million by 2031, at a CAGR of 7.95% in the forecast period (2024-2031).

Several significant worldwide firms vying for market supremacy define the competitive landscape of the inhaled nitric oxide market. To improve their position in the industry, major firms like Novoteris, Linde plc, Praxair Inc., Mallinckrodt Pharmaceuticals, and Air Liquide are actively working on new products, forming strategic alliances, and merging. To take advantage of the rising demand for inhaled nitric oxide therapy globally, these companies are concentrating on broadening their product offerings and geographic reach. 'Perma Pure LLC (US)', 'Merck KGaA (Germany)', 'Zylo Therapeutics Inc. (US)', 'HALMA PLC (UK)', 'Pieris Pharmaceuticals (US)', 'Air Liquide Healthcare (France)', 'Bellerophan Therapeutics Inc. (US)', 'Mallinckrodt Pharmaceuticals (Novoteris) (US)', 'Matheson Tri-Gas Inc. (US)', 'BOC Healthcare (UK)', 'Vero Biotech (US)', 'Nu-Med Plus Inc. (US)', 'Praxair Distribution Inc. (US)', 'LINDE PLC (UK)', 'Beyond Air', 'Taiyo Nippon Sanso Corporation', 'Praxair, Inc. (now part of Linde plc)', 'Novoteris, LLC', 'Nu-Med Plus, Inc.'

The market for inhaled nitric oxide is significantly driven by the rising prevalence of respiratory illnesses. The need for inhaled nitric oxide as a therapy option is anticipated to increase if these disorders continue to impact many people globally. Exposure to air pollution, cigarette smoke, and occupational risks are examples of environmental contaminants that can have a substantial impact on respiratory health and raise the chance of acquiring respiratory disorders. The ageing population's weakening immune systems and inherent changes in lung function make them more vulnerable to respiratory diseases. It is anticipated that the prevalence of respiratory illnesses would increase as the world's population ages.

Growing Impact of Asthma and COPD: Among the most prevalent respiratory illnesses impacting the public are asthma and COPD, both of which can be fatal and impair a patient's daily ability to breathe. Chronic asthma is a disorder that causes the lungs' air passageways to expand and constrict, which results in attacks of dyspnea, bronchospasm, and reversible airflow blockage. A significant increase in cigarette usage exacerbates the symptoms of COPD and asthma. Furthermore, because of increased industrialization, there are now more occurrences of COPD and asthma, which could drive up demand for inhaled nitric oxide during the projection period.

Throughout the anticipated period, North America is anticipated to maintain its prominent position in the inhaled nitric oxide market. This is since there are recognized organizations for research and development as well as a modern healthcare infrastructure. To deliver inhaled nitric oxide therapy, North America offers sophisticated healthcare facilities, including clinics and hospitals, as well as the knowledge and resources to do so. During the anticipated period, the inhaled nitric oxide market is expected to grow at the quickest rate in Europe. This is due to the presence of significant regional players, continuing research, and clinical trials regarding the safety and effectiveness of inhaled nitric oxide. In Europe, pulmonary hypertension is a prevalent ailment that impacts many people.

Feedback From Our Clients

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

Inhaled Nitric Oxide Market Competitive Landscape

Inhaled Nitric Oxide Market Report Snapshots

Want to customize this report?

FAQs

Request Free Customization

Feedback From Our Clients

$5,300

Inhaled Nitric Oxide Market Competitive Landscape

Inhaled Nitric Oxide Market Report Snapshots

Want to customize this report?

FAQs

What is the market size of Inhaled Nitric Oxide Market?

Who are the key vendors in the Inhaled Nitric Oxide Market?

What is the key driver of Inhaled Nitric Oxide Market?

What is the key market trend for Inhaled Nitric Oxide Market?

Which region accounted for the largest share in Inhaled Nitric Oxide Market?

Request Free Customization

Related Reports

Feedback From Our Clients

$5,300